COMMUNIQUÉS West-GlobeNewswire

Présentation de TiGenix à l'occasion de la 7ème Conférence TERMIS-UE à Davos (Suisse)

23/06/2017 - 07:00

COMMUNIQUÉ DE PRESSE Présentation de TiGenix à l'occasion de la 7 ème Conférence TERMIS-UE à Davos (Suisse) Louvain (BELGIQUE) - vendredi 23 juin 2017, 07h. CEST - TiGenix NV (Euronext Brussels et NASDAQ : TIG), société [...]

Addex Shareholders Approved all Board Proposals at 2017 Annual General Meeting

23/06/2017 - 07:00

Roger Mills elected to the Addex Board of Directors Geneva, Switzerland, 23 June 2017 - Addex Therapeutics (SIX: ADXN), announced today that its shareholders approved all the proposals of the board of directors at its [...]

Novartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)

22/06/2017 - 23:42

Approval provides first targeted treatment in the US specifically for BRAF V600E mutation-positive metastatic NSCLC More than 60% of treatment-naïve and previously treated patients with BRAF V600E mutant metastatic [...]

Targovax ASA: Mandatory notification of trade by primary insider in relation to exercise of employee options

22/06/2017 - 22:15

1. Exercise of employee share options Berit Iversen, VP CMC of Targovax (the "Primary Insider"), has on 22 June 2017 subscribed for 25,000 shares in Targovax ASA at a price of NOK 7.5 per share in connection with her [...]

Novo Nordisk A/S: CHMP endorses EU label update of Saxenda® based on the LEADER trial

22/06/2017 - 20:19

PR170622_LEADER_EU_CHMP_Saxenda_UK This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely [...]

GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 mai 2017

22/06/2017 - 18:26

Communiqué de presse Villepinte, le 22 juin 2017 DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l' [...]

AB Science présente de nouvelles données positives de son étude de phase 3 dans la mastocytose systémique sévère au 22ème Congrès international de de l'Association Européenne d'Hématologie (AEH)

22/06/2017 - 17:41

Paris, 22 juin, 17h45 AB Science présente de nouvelles données positives de son étude de phase 3 dans la mastocytose systémique sévère au 22ème Congrès international de de l'Association Européenne d'Hématologie (AEH) Le [...]

AB Science Presents Supportive Data from its Phase 3 Study in Severe Systemic Mastocytosis at the 22nd Congress of the European Hematology Association (EHA)

22/06/2017 - 17:41

Paris, June 22, 2017, 5.45pm AB Science Presents Supportive Data from its Phase 3 Study in Severe Systemic Mastocytosis at the 22 nd Congress of the European Hematology Association (EHA) Abstract Selected for [...]

Minerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in Phase 3 Trial for the Treatment of Negative Symptoms in Patients With Schizophrenia

22/06/2017 - 14:30

New formulation observed to improve safety margin while offering bioequivalent exposure to prior formulation Company to proceed with initiation of Phase 3 trial on schedule in second half of 2017 CMC scale-up work for [...]

Auris Medical to Host Scientific Symposium at IFOS ENT World Congress in Paris

22/06/2017 - 14:00

Zug, Switzerland, June 22, 2017 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced [...]

Oriola Corporation has rearranged its long-term revolving credit facility and term loan agreement

22/06/2017 - 14:00

Oriola Corporation Stock Exchange Release 22 June 2017 at 15.00 Oriola Corporation has rearranged its long-term revolving credit facility and term loan agreement Oriola Corporation has agreed to rearrange its long-term [...]

Summit Presents Data from Phase 1 Clinical Programme of Ezutromid at the EPNS Congress

22/06/2017 - 13:00

Summit Therapeutics plc ('Summit', or 'the Company') SUMMIT PRESENTS DATA FROM PHASE 1 CLINICAL PROGRAMME OF EZUTROMID AT THE EUROPEAN PAEDIATRIC NEUROLOGY SOCIETY CONGRESS Oxford, UK, 22 June 2017 - Summit Therapeutics [...]

Verona Pharma Appoints Dr. Desiree Luthman as Vice President of Regulatory Affairs

22/06/2017 - 13:00

LONDON, June 22, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]

UPM launches a new, economical solution for the thin print market

22/06/2017 - 13:00

(UPM, Helsinki, 22 June 2017 at 14:00 EET) - The Biofore company UPM has launched a new solution for the thin print market. The revolutionary paper, UPM EcoLite, has been specially designed to meet the needs of [...]

UPM propose une nouvelle solution économique pour le marché des papiers minces

22/06/2017 - 13:00

(UPM, Helsinki, 22 juin 2017, 14h00 EET) - Le fabricant de papier UPM lance une nouvelle solution pour le marché des papiers minces. Ce papier révolutionnaire, UPM EcoLite, a été spécialement conçu pour répondre aux [...]

Targovax ASA: Exercise of employee share options and settlement of restricted stock units in Targovax ASA

22/06/2017 - 11:13

Reference is made to the stock exchange notice of 14 June 2017 regarding increase of the share capital in Targovax ASA (the "Company") relating to exercise of employee options and settlement of restricted stock units. [...]

Phase 2a trial results support development of dasiglucagon in the iLet pump system for type 1 diabetes

22/06/2017 - 08:47

Dasiglucagon* is a potential first-in-class glucagon analog for prevention and treatment of low blood sugar in type 1 diabetes using an automated pump system Dasiglucagon was dosed using the iLet (TM) platform, a state- [...]

Herantis Pharma's Lymfactin study advances to last patient cohort, company announces initial plans for continued development

22/06/2017 - 08:00

Herantis Pharma's Lymfactin study advances to last patient cohort, company announces initial plans for continued development Herantis Pharma Plc Company release 22 June 2017 at 9:00 am Herantis Pharma Plc's ("Herantis [...]

Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack

22/06/2017 - 07:15

Phase III CANTOS study met the primary endpoint, a composite of heart attack, stroke and cardiovascular death, showing that ACZ885 (canakinumab) in combination with standard of care therapy reduces cardiovascular risk [...]